StemoniX Revenue and Competitors

Claim your profile

Location

$37.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • StemoniX's estimated annual revenue is currently $1.6M per year.(i)
  • StemoniX's estimated revenue per employee is $77,500
  • StemoniX's total funding is $37.6M.

Employee Data

  • StemoniX has 20 Employees.(i)
  • StemoniX grew their employee count by -41% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.5M74-9%N/AN/A
#2
$10.1M65-2%N/AN/A
#3
$16.3M1053%$20.5MN/A
#4
$16.4M10610%$39.1MN/A
#5
$10.1M6520%N/AN/A
#6
$20.6M133-1%N/AN/A
#7
$10.2M6669%N/AN/A
#8
$14.4M93-7%N/AN/A
#9
$3.3M21-22%N/AN/A
#10
$4M63-5%N/AN/A

Our mission is to accelerate the discovery of new medicines with physiologically-relevant, structured human cells that improve cell-based assay outcomes. We develop and scalably manufacture human induced pluripotent stem (iPS) cell-derived cardiac and neuronal platforms for drug discovery and development. Predictive, accurate, and consistent, our human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. We also collaborate with drug discovery organizations to test their compounds with our in-house screening capabilities, create new cell-based models, and operationalize their human iPS cells at large scale for high throughput screening. StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity. StemoniX microBrain® products in high density formats are physiologically relevant with biology, activity, functional maturity that mimic native human brain tissue. Available pre-plated to simplify your workflow, microHeart and microBrain are delivered in ambient conditions and ready for assay use soon after delivery. With leading-edge iPSC technologies, we are helping global institutions bring the most promising medicines to patients. Contact us at info@stemonix.com to discuss how StemoniX products and services can accelerate your discoveries.

keywords:N/A

$37.6M

Total Funding

20

Number of Employees

$1.6M

Revenue (est)

-41%

Employee Growth %

N/A

Valuation

N/A

Accelerator

StemoniX News

2022-04-13 - Vyant Bio (NASDAQ:VYNT) Downgraded by Zacks Investment ...

StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. vivoPharm offers...

2021-01-12 - StemoniX to Participate in Biotech Showcase(TM) Digital 2021

Maple Grove, Minnesota--(Newsfile Corp. - January 11, 2021) - StemoniX, a biotech company changing how new drugs are discovered, announced today their participation at the 2021 Biotech Showcase™ being held January 11-15th as part of OrganAi, a joint venture between StemoniX and Atomwise. The com ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M2082%N/A
#2
$3.8M2018%N/A
#3
$2M20N/AN/A
#4
$3.4M20-5%N/A
#5
$3.5M20-50%N/A